<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>109(8)</volume><submitter>Ter Maaten JM</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Loop diuretics are frequently prescribed to patients with heart failure and reduced ejection fraction (HFrEF) for the treatment of congestion; however, they might hamper uptitration of inhibitors of the renin-angiotensin system.&lt;h4>Methods&lt;/h4>Loop diuretic dose at baseline was recorded in 2338 patients with HFrEF enrolled in BIOSTAT-CHF, an international study of HF patients on loop diuretic therapy who were eligible for uptitration of angiotensin-converting enzyme inhibitors (ACEi)/mineralocorticoid receptor antagonists (MRA). The association between loop diuretic dose and uptitration of ACEi/MRA to percentage of target dose was adjusted for a previously published model for likelihood of uptitration and a propensity score.&lt;h4>Results&lt;/h4>Baseline median loop diuretic d</pubmed_abstract><journal>Clinical research in cardiology : official journal of the German Cardiac Society</journal><pagination>1048-1059</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7375987</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction.</pubmed_title><pmcid>PMC7375987</pmcid><pubmed_authors>Ter Maaten JM</pubmed_authors><pubmed_authors>Martens P</pubmed_authors><pubmed_authors>Zannad F</pubmed_authors><pubmed_authors>Cleland JG</pubmed_authors><pubmed_authors>Metra M</pubmed_authors><pubmed_authors>Hillege HL</pubmed_authors><pubmed_authors>Damman K</pubmed_authors><pubmed_authors>Lang CC</pubmed_authors><pubmed_authors>Samani NJ</pubmed_authors><pubmed_authors>Voors AA</pubmed_authors><pubmed_authors>Dickstein K</pubmed_authors><pubmed_authors>Anker SD</pubmed_authors><pubmed_authors>Filippatos G</pubmed_authors><pubmed_authors>Mullens W</pubmed_authors><pubmed_authors>Ng LL</pubmed_authors><pubmed_authors>Ponikowski P</pubmed_authors><pubmed_authors>van Veldhuisen DJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction.</name><description>&lt;h4>Background&lt;/h4>Loop diuretics are frequently prescribed to patients with heart failure and reduced ejection fraction (HFrEF) for the treatment of congestion; however, they might hamper uptitration of inhibitors of the renin-angiotensin system.&lt;h4>Methods&lt;/h4>Loop diuretic dose at baseline was recorded in 2338 patients with HFrEF enrolled in BIOSTAT-CHF, an international study of HF patients on loop diuretic therapy who were eligible for uptitration of angiotensin-converting enzyme inhibitors (ACEi)/mineralocorticoid receptor antagonists (MRA). The association between loop diuretic dose and uptitration of ACEi/MRA to percentage of target dose was adjusted for a previously published model for likelihood of uptitration and a propensity score.&lt;h4>Results&lt;/h4>Baseline median loop diuretic d</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Aug</publication><modification>2025-04-05T12:42:34.136Z</modification><creation>2025-04-05T12:42:34.136Z</creation></dates><accession>S-EPMC7375987</accession><cross_references><pubmed>32002631</pubmed><doi>10.1007/s00392-020-01598-w</doi></cross_references></HashMap>